



2026

PROBIOTIC YOGURT FORMULATIONS

for Enhancing Endogenous
GLP-1 Secretion

Content



Introduction

- When the gut became the pharmacist
- Executive Summary



Taxonomy



Patent Insights

- Overall filing trend
- Filing vs Grant trend
- Geo Protection Growth
- Average Time to Grant
- Current Legal Status
- Remaining Life
- Top Jurisdictions
- Top Assignees
- Assignee Type
- Assignee Type Innovation Timeline
- Assignee Type Geographical Footprint



Technology Fragmentation

- Technology Taxonomy
- Filing trends



Market Insights

- Market Overview
- Current Market
- Market Forecast
- Market Potential
- Key Market Players and their Products



Appendix

- Taxonomy Definitions
- Country Table
- Disclaimer



When the gut became the pharmacist

The probiotic yoghurt industry spent two decades selling digestive comfort. The next decade will be defined by a single, higher-order question: can a spoonful of fermented dairy shift the hormonal architecture of appetite itself?

In 2023, semaglutide entered the cultural mainstream. By 2025, GLP-1 receptor agonists were generating over \$50 billion in annual pharmaceutical revenues, a figure that no food company could ignore. But the drugs, remarkable as they are, are not the story. The story is what they revealed: that a single hormone, secreted naturally in the gut, has outsized control over satiety, metabolism, and body weight.


Consumers understood this faster than most food companies anticipated. Google searches for "foods that boost GLP-1" increased. The consumer was already asking the question. The industry needed to be ready with the answer.

Why yoghurt and why now?

Yoghurt is not an accidental vehicle. It is the most structurally advantaged food format for GLP-1 delivery for three inter-related reasons. First, it already delivers live microbial cultures, the biological agents that ferment prebiotic fibers into the short-chain fatty acids (SCFAs) that directly stimulate L-cells in the distal gut to secrete GLP-1. Second, its low pH and gel matrix are unusually compatible with the fiber types that carry the strongest mechanistic evidence. Third, and perhaps most importantly, consumers already believe yoghurt is good for their gut no category repositioning required, only an upgrade of the underlying science.

The timing is set by a convergence of four forces that did not fully co-exist before 2024: a mature body of peer-reviewed evidence linking specific prebiotic fibers to GLP-1 secretion; a consumer cohort educated on GLP-1 biology by pharmaceutical advertising; a supply chain for high-purity prebiotic ingredients that is now competitively priced; and a regulatory environment particularly in Japan's FOSHU framework that provides commercially deployable claim templates.

The Endogenous GLP-1 Pathway via Dietary Fiber



The Science in Brief

The L-cell mechanism

GLP-1 is secreted by enteroendocrine L-cells concentrated in the ileum and colon. Propionate and butyrate. SCFAs produced when gut bacteria ferment prebiotic fibers bind directly to FFAR2 and FFAR3 receptors on these cells, triggering GLP-1 exocytosis. This is the best-validated dietary pathway to endogenous GLP-1 elevation.

The microbiome multiplier

Sustained prebiotic intake selectively enriches *Akkermansia muciniphila* and *Bifidobacterium longum* both independently correlated with higher fasting GLP-1 levels. This cumulative remodeling effect amplifies the acute fiber-to-SCFA response and explains why 8–12 week trials outperform shorter studies.

The synbiotic advantage

The combination of a specific prebiotic fiber with a matched probiotic strain consistently outperforms either ingredient alone. SCF paired with *B. lactis* HN019 shows a 22% greater propionate response vs. either ingredient in isolation the core formulation principle of the highest-performing SKUs on market today.

Dose and form matter

Not all prebiotic fibers produce equivalent GLP-1 signals. Long-chain chicory inulin (HP grade) outperforms short-chain FOS at identical doses due to its preferential fermentation in the distal colon. The formulation decision which fiber, at what dose, with which strain is the central competitive variable in this category.

THE CENTRAL THESIS

The pharmaceutical GLP-1 moment has educated consumers, established a vocabulary, and created a demand signal. The food industry's task is not to compete with Ozempic, it is to occupy the metabolic health aspiration that Ozempic made legible to a mass audience. Probiotic yoghurt, correctly formulated, is the most credible, accessible, and scalable vehicle for that occupation.

Executive Summary



The GLP-1 receptor agonist drug class anchored by semaglutide has crossed from pharmaceutical footnote to cultural phenomenon, generating over \$50 billion in 2025 revenues and resetting consumer expectations around appetite, satiety, and metabolic health. Simultaneously, a body of peer-reviewed evidence now confirms that specific prebiotic dietary fibers can stimulate endogenous GLP-1 secretion from L-cells in the distal gut without a prescription, without an injection, and at a cost structure that fits inside a grocery cart.

Yoghurt sits at the exact intersection of these forces: a trusted, refrigerated, daily-consumption vehicle that already carries probiotic credentials and a health positioning consumers believe. Innovators who understand which prebiotic fibers unlock GLP-1 pathways and how to formulate, claim, and communicate them will capture disproportionate value in what is poised to become a \$4.2B premium segment by 2030.

- Soluble Corn Fiber (SCF) has emerged as the dominant prebiotic carrier in North American launches favoured for its clean taste, processing stability, and strong GLP-1 mechanistic story. Chicory inulin/FOS holds European leadership.
- Japan's FOSHU regulatory framework has created a commercially proven pathway for GLP-1 yoghurt claims that Western brands have systematically under-leveraged.
- Plant-based prebiotic yoghurt is experiencing a bifurcated trajectory: premium innovation clusters around acacia fibre and GOS, while mass-market oat-based SKUs chase volume over metabolic credentials.
- India represents the single largest untapped white space: a 1.4 billion person market with deep dahi culture, rising metabolic disease burden, and zero major SKUs carrying a prebiotic GLP-1 positioning.
- Amul, Mother Dairy, Heritage, Verka, Milky Mist add probiotic cultures but generally do NOT add prebiotic fiber; Epigamia is the exception declaring Pectin as prebiotic
- Private label is disrupting prebiotic yoghurt faster than any other functional food segment, Kroger, Tesco, and Rewe have launched prebiotic tiers within 18 months of category creation by branded players.
- Lifeway Kefir: 25–30 Billion CFU; 12 cultures which is highest of consumer dairy products in this list

Classifying the Science: Probiotic Yogurt & GLP-1 Secretion

Probiotic Yogurt Formulations for Enhancing Endogenous GLP-1 Secretion

1 PROBIOTIC STRAINS

- 1.1 Lactic Acid Bacteria (LAB)
 - 1.1.1 Lactobacillaceae Family
 - 1.1.2 Streptococcaceae Family
- 1.2 Bifidobacterium
- 1.3 Akkermansia
- 1.4 Bacillus & Spore-Forming Probiotics
- 1.5 Fungal & Yeast Probiotics
- 1.6 Other

2 FERMENTED DAIRY FORMULATIONS

- 2.1 General
- 2.2 Yogurt
- 2.3 Kefir/leben

3 BIOACTIVE INGREDIENTS & FUNCTIONAL ADDITIVES

- 3.1 Prebiotics
 - 3.1.1 General
 - 3.1.2 Fructans
 - 3.1.3 Non-Digestible Carbohydrates & Fibers
 - 3.1.4 Dietary fiber
 - 3.1.5 Specialized & Novel Oligosaccharides
 - 3.1.6 Polyphenols
- 3.2 Proteins and plant extracts
- 3.3 Other functional additives (Vitamins, bioactive peptides)

4 YOGURT MATRIX TYPE

- 4.1 Animal-based
- 4.2 Plant-based


5 GLP-1 PATHWAY

- 5.1 Direct GLP-1 Stimulation & Secretion
 - 5.1.1 Bacterial Secretion/Stimulation
 - 5.1.2 Nutritional Stimulants
- 5.2 DPP-4 Inhibition
- 5.3 Recombinant GLP-1 Expression
- 5.4 Microbiota Modulation

6 THERAPEUTIC APPLICATIONS & CLINICAL OUTCOMES

- 6.1 Metabolic Disorders
 - 6.1.1 Glucose Dysregulation
 - 6.1.2 Lipid & Cholesterol Disorders
 - 6.1.3 Obesity & Weight Management
 - 6.1.4 Others
- 6.2 Cardiovascular & Circulatory Diseases
- 6.3 Gastrointestinal (GI) & Hepatic Disorders
- 6.4 Musculoskeletal & Wasting Syndromes
- 6.5 Neurological & Psychological Disorders
- 6.6 Inflammatory, Immune & Systemic Condition

Overall Filing Trend



Patent activity remained relatively limited until the mid-2010s, indicating early-stage exploration rather than aggressive commercialization.

The sharp rise beginning in 2019 marks a strategic inflection point, reflecting growing industry interest in microbiome-driven metabolic modulation and incretin biology.

The strong filing activity in 2024–2025 indicates increasing competition to secure IP around:

- probiotic strain combinations
- synbiotic formulations
- SCFA-mediated GLP-1 stimulation
- appetite and glycemic regulation technologies

The trend suggests future competitive advantage will likely depend on proprietary strain-function relationships and validated metabolic efficacy rather than conventional nutritional positioning alone.

The trend closely parallels the commercial expansion of GLP-1 therapeutics, highlighting convergence between functional foods, microbiome science, and metabolic healthcare.


Sustained filing momentum from 2021 onward suggests the sector is transitioning from conventional probiotic wellness products toward clinically positioned metabolic nutrition platforms.

From an IP perspective, the sector is evolving from broad wellness positioning toward evidence-backed “food-as-biologic” innovation, likely increasing both patent quality thresholds and regulatory scrutiny in the coming years.

Emerging patents are likely expanding beyond composition claims into areas such as microbiome modulation pathways, fermentation engineering, and personalized nutrition applications.

Filing Trend vs Grant Trend

Patenting Trends



Patent filings accelerated significantly after 2019, indicating growing industry and research interest in probiotic formulations targeting endogenous GLP-1 secretion.

The sharp rise in filings during 2019 suggests an early innovation surge and expanding competitive activity in the domain.

Grant publications began increasing notably from 2021 onward, reflecting gradual maturation of early-stage patent applications.

The continued gap between filings and grants highlights that much of the landscape is still in a developing or pending-IP phase.

Strong filing momentum in 2024–2025 indicates sustained confidence in the commercial and therapeutic potential of metabolic-health probiotics.

The rise in granted patents by 2025 suggests increasing patent office acceptance and strengthening enforceability of technologies in this space.


The trend reflects a transition from exploratory research toward more structured and commercially oriented IP strategies.

Increasing grant activity may intensify future competition around formulation claims, microbial strains, and functional-health mechanisms.

The absence of filing decline despite increasing grants indicates that the technology space remains far from saturation.

Overall, the data suggests the sector is entering a high-growth commercialization phase driven by both scientific validation and strategic IP expansion.

Average Time to Grant



Korea demonstrates the fastest average grant timeline, indicating a highly efficient examination environment for probiotic and functional-health patents.

Japan also shows relatively quick grant timelines, supporting faster commercialization and enforceability in the region.

The United States maintains moderate grant timelines, balancing rigorous examination with commercially valuable patent protection.

Europe exhibits longer grant durations, reflecting stricter examination standards and broader claim scrutiny.

Eurasian filings show the longest average time to grant, suggesting slower procedural or administrative progression.

Russia also reflects comparatively extended grant timelines, potentially impacting speed-to-market advantages.


Faster grant jurisdictions may become preferred filing destinations for early enforceability and licensing leverage.

Longer examination timelines in certain jurisdictions could increase prosecution costs but may also result in more defensible patents.

The variation in grant timelines highlights the importance of jurisdiction-specific IP strategy in metabolic-health innovation.

Overall, companies appear to balance rapid-grant jurisdictions for early protection with slower, high-value markets for long-term commercial strength.

Top Jurisdiction



China leads the patent landscape with 28 filings, indicating aggressive innovation activity and rapid commercialization efforts in probiotic yogurt formulations targeting metabolic health and GLP-1 support.

The United States follows closely with 23 filings, reflecting strong commercial maturity and increasing convergence between functional nutrition, microbiome science, and obesity-management ecosystems.

South Korea's 10 filings highlight its growing specialization in advanced fermentation technologies, probiotic engineering, and functional dairy innovation despite a comparatively smaller market size.

Europe's 9 filings suggest a more selective, science-driven innovation approach, likely influenced by stricter regulatory scrutiny around probiotic and health-related claims.

The jurisdictional spread demonstrates that probiotic yogurt is evolving beyond digestive wellness into a broader metabolic-health and satiety-support category.

Asian jurisdictions, particularly China and South Korea, are driving early filing momentum, suggesting faster innovation cycles and heightened competition in microbiome-focused dairy products.

Patent activity increasingly extends beyond conventional yogurt formulations into probiotic strain combinations, synbiotic systems, fermentation optimization, and endogenous GLP-1 modulation technologies.

The growing concentration of filings around microbiome-linked metabolic health reflects the industry's shift toward "food as adjunct therapy" alongside pharmaceutical GLP-1 treatments.

Market Overview

GLP-1s Are Turning Yogurt Into a Metabolic-Health Platform

America's eating less but wants more from every bite. That's the GLP-1 effect, and yogurt is one of the biggest winners.

Nearly a quarter of U.S. households (23%) now have someone on a GLP-1 like Ozempic, Wegovy, or Zepbound and Circana projects that cohort will drive 35% of all U.S. food and beverage units sold by 2030. These aren't casual shoppers: appetite suppression means every calorie has to work harder, so users are hunting for protein density, gut comfort, and steady energy in smaller portions exactly yogurt's lane.

The science tailwind is real too. In March 2024, the FDA granted yogurt its first-ever qualified health claim, linking 3 servings a week to reduced type 2 diabetes risk, a regulatory green light landing right as GLP-1 adoption exploded. Big dairy is already repositioning. Danone (which petitioned for that FDA claim) and Lactalis are pushing high-protein, low-sugar, fiber-forward cultured dairy lines squarely at this consumer.

The emergence of GLP-1 friendly probiotic yogurt reflects a broader structural shift occurring across the food, nutrition, and metabolic health industries as the rapid adoption of GLP-1 receptor agonist drugs such as Ozempic, Wegovy, and Zepbound begins reshaping consumer eating behavior and food product development priorities.

\$22.0B Probiotic yogurt market, 2025	\$53.4B Projected market size, 2035	\$66.5B GLP-1 drug market, 2025
---	---	---


GLP-1 pharmaceutical anchor: The global GLP-1 analogues market is estimated at \$66.48 billion in 2025. By 2030, more than 30 million Americans could be on a GLP-1 treatment, up from 10 million in 2026, based on J.P. Morgan estimates.

GLP-1 functional food segment: The global GLP-1 drug impact on food & beverage consumer market was valued at \$4.6 billion in 2025 and is projected to surge to \$26.1 billion by 2034, registering an 18.2% CAGR.

Consumer behaviour: The number of Americans taking semaglutide or tirzepatide more than doubled in the past year and a half, with 12.4% of respondents taking the medications, per the Gallup National Health and Well-Being Index.

Regional: India is poised for the fastest growth in Asia Pacific, at a 12.34% CAGR between 2025 and 2030, per Mordor Intelligence.

Key Players



Pro-biotic Strains

- S. thermophilus;
- L. bulgaricus
- Skyr cultures

Arla Skyr High Protein Icelandic-Style Yogurt – Plain

Viby, Denmark Skyr / Icelandic Yogurt EU / UK / Global

Serving Size	500g / 150g
Protein (per 100g)	10.6
Fat content	Fat content
Added Sugar	0g
Lactose-free	No
Plant-based	No
Pre-biotic fiber type	None Declared
Pre-biotic fiber amount	0g

- ~11 g protein/100 g via Icelandic-style straining process
- 2Zero fat and zero added sugar, clean Scandinavian label
- 3 Available plain and flavoured across EU, UK, and US markets
- Non GMO, Gluten Free



Pro-biotic Strains

- L. lactis
- L. cremoris
- L. acidophilus
- Bifidobacterium spp

Biolife Greek Probiotic

Brooklyn Greek-Style Strained Kefir USA

Serving Size	16 oz
Protein (per 100g)	3.8 g
Fat content	Low fat
Added Sugar	Low / 0 g added sugar
Lactose-free	Naturally low lactose
Plant-based	No
Pre-biotic fiber type	None declared
Pre-biotic fiber amount	0 g

- Greek-style strained kefir formulation, functional fermented dairy positioning
- Higher protein profile compared to conventional kefir
- Thick and creamy texture, probiotic-rich composition
- Non-GMO, Gluten-Free

Key Players



Pro-biotic Strains

12 live active kefir cultures,
typically 10–25 Billion CFU

Biolife Amish Probiotic Kefir Drink – Amish Style

Brooklyn

Kefir

USA

Serving Size	32 oz bottle
Protein (per 100g)	3.8 g
Fat content	Whole milk
Added Sugar	Natural lactose only
Lactose-free	Naturally low lactose
Plant-based	No
Pre-biotic fiber type	None declared
Pre-biotic fiber amount	0 g

- Traditional Amish-style kefir, Whole milk formulation
- Grain-based culture heritage, Minimal processing
- Regional US specialty distribution
- No artificial additives, Gluten-Free



Pro-biotic Strains

- L. bulgaricus
- S. thermophilus
- L. acidophilus
- Bifidobacterium
- L. casei & L. paracasei

Chobani Complete Greek Yogurt

Norwich, NY

Greek Yogurt

USA

Serving Size	5.3 oz (150 g) cup
Protein (per 100g)	10 g
Fat content	Low fat (2–2.5 g/serving)
Added Sugar	0 g added sugar
Lactose-free	Yes
Plant-based	No
Pre-biotic fiber type	Chicory Root Fiber; Fruit Pectin
Pre-biotic fiber amount	~3 g per 5.3 oz serving

- 15 g complete protein containing all 9 essential amino acids
- Combined prebiotic + probiotic positioning
- Non-GMO formulation, Gluten-free positioning, Kosher labels
- Multi-strain live probiotic cultures, Billions of live cultures

Contact Information

India Office (HQ)



Address

DLF Forum, Cyber City, DLF Phase 3, Sector 24,
Gurugram, Haryana 122002



+91 931-171-1163



surbhi@intelacia.com; info@intelacia.com

USA Office



Address

11801 Domain Blvd 3rd Floor, Austin, TX
78758, United States



+1 512-877-5090



surbhi@intelacia.com; info@intelacia.com

Gurugram



Address

21-B, 91SpringBoard, Udyog Vihar Sector 18,
Gurugram, Sarhol, Haryana – 122015



+91 931-171-1163



surbhi@intelacia.com; info@intelacia.com



+91 931-171-1163



info@intelacia.com



www.Intelacia.com



Follow us for latest IP insights